CASP9 and breast carcinoma: Breast cancer: Oral dose (100 mg/kg)/3 days inhibited tumor growth and increased caspase-9 levels in MDA-MB-231 in the BALB/c mouse-xenograft model; −0.1% in the drinking water/day during 6.6 w promoted the antitumoral activity in female Balb/c; −50 mg/kg/po decreased the tumor size in rats